Boston BioProducts Receives ISO 13485:2016 Quality Certification
6.4.2023 16:03:00 EEST | Business Wire | Press release
Boston BioProducts, a longstanding manufacturer of fundamental reagents for the life sciences, today announced that its quality management system (QMS) has achieved ISO 13485:2016 certification from TÜV SÜD America for the medical device manufacturing and supply of buffers, solutions, media, and reagents serving research, diagnostics, and therapeutics applications. Achieving this certification signifies Boston BioProducts’ commitment to high-quality standards across the entire reagent manufacturing process.
ISO 13485:2016 is considered the industry standard for QMS systems designed for medical devices and related services. It sets a robust and reproducible framework for the design, development, and manufacturing of products that meets customer and regulatory requirements. The International Organization for Standardization (ISO) is a global, independent publisher of standards governing the safety, reliability, and quality of manufactured products. TÜV SÜD America is among the most respected and accomplished certification bodies in the market serving thousands of registrations worldwide.
“This major company milestone further supports Boston BioProducts’ path to becoming a premier partner for contract reagent development and manufacturing across research, diagnostics, and therapeutics”, said Neil Sharma, General Manager of Boston BioProducts. “Scientists, assay developers, and manufacturing engineers can rely on a single source for the customization, testing, and supply of their process-critical buffers, solutions, and media reagents whether starting from innovation to publication, RUO to IVD, or preclinical to GMP.”
With the ISO 13485:2016 certification, Boston BioProducts is better positioned to support a range of growing regulated applications such as in vitro diagnostics, clinical trial assays , and cell and gene therapy manufacturing. This elevated quality management system complements the company’s flexible custom reagent manufacturing and rapid product delivery.
About Boston BioProducts
For nearly 30 years, Boston BioProducts (BBP) has manufactured and supplied fundamental reagents (buffers, solutions, media, and more) to researchers, diagnostic and technology platforms, and drug developers worldwide. With its custom reagent manufacturing services, BBP becomes an extension of your lab with flexible parameters to design the ideal research and manufacturing tools. Its mission is to increase the reproducibility of product- and process-critical reagents that keep your science consistent and moving forward. For more information, please visit www.bostonbioproducts.com and follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005030/en/
Contact information
Boston BioProducts Marketing
marketing@bostonbioproducts.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Cloud Ventures Announces Final Close of Blue Cloud Ventures V2.6.2026 17:35:00 EEST | Press release
Blue Cloud Ventures (BCV), a venture growth firm focused on investing in enterprise software companies, announced the final close of its fifth fund, Blue Cloud Ventures V (BCV V). This milestone reinforces the firm’s continued mission to back category-defining companies that are poised to thrive in the age of AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602186634/en/ At the core of BCV’s strategy is building deep conviction in and backing companies that possess the potential to define or reshape entire industries. With BCV V, the firm is doubling down on its AI-first investment thesis, aiming to back and support visionary teams on their long-term growth journey as they build the systems that will serve as the backbone of the modern enterprise. Blue Cloud typically invests between $10 and $30 million as a lead, co-lead, or co-investor. Beyond support with strategy, recruiting, and customer introductions, the firm pro
IQM, a Global Leader in Quantum Computing, and Real Asset Acquisition Corp. Announce Upsized USD 146 million PIPE with New Commitment from Ilmarinen2.6.2026 17:17:00 EEST | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”) and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced an additional PIPE commitment from Ilmarinen in connection with the previously announced business combination between IQM and RAAQ. Ilmarinen’s new commitment comes alongside commitments from other leading institutional investors in the previously announced USD 134 million PIPE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602993879/en/ IQM quantum computer The incremental PIPE provides additional funding on top of the previously announced USD 134 million in PIPE financing proceeds to be used to accelerate IQM’s technology and commercial development towards fault-tolerant quantum computing, further advancing its position as a leading provider of quantum computers. Headquartered in
Laserfiche Launches on AWS Marketplace, Bringing Intelligent Content Management to the Enterprise2.6.2026 17:00:00 EEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management — has partnered with AWS to make Laserfiche available through AWS Marketplace. This collaboration enables AWS customers to seamlessly procure Laserfiche’s document management platform to manage content, automate workflows and implement agentic AI capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602537198/en/ Laserfiche intelligent content management is now available to procure directly through AWS Marketplace. “We’re excited about this evolution of our long-standing partnership with AWS,” said Thomas Phelps, Laserfiche senior vice president of corporate strategy and CIO. “AWS Marketplace provides a near-frictionless experience for Laserfiche direct customers who want to accept negotiated private offers, manage billing and payment history, and apply eligible purchases toward their AWS Enterprise Discount Program (EDP) commitments — all thr
Experian Brings Trusted Agentic AI to Financial Services With the Launch of Agent Operating System™2.6.2026 16:05:00 EEST | Press release
Experian today announces the launch of the Agent Operating System™, a trusted agentic AI layer within the Experian Ascend Platform, unveiled at Money20/20 Europe. The Experian Agent Operating System is designed to help financial services organisations move successfully beyond AI experimentation and safely scale agentic AI to transform decision-making, customer experiences, and day-to-day operations. It enables AI agents from Experian, clients and partners to work together through a common trust, semantic and orchestration layer, supported by clear controls, auditability and human oversight. The launch comes as financial services firms accelerate investment in AI but continue to face major barriers to scaling adoption. New Experian research* shows that nearly half of global organisations (48%), say integrating data into AI workflows remains difficult, while a third cite poor data lineage and a further third say data is siloed across teams and systems. At the same time, consumers are inc
High Q Technologies and Creative Biostructure Announce Strategic Partnership Expanding Global Access to Quantum-Enabled EPR Spectroscopy2.6.2026 16:00:00 EEST | Press release
High Q Technologies, a developer of quantum-enabled electron paramagnetic resonance (EPR) spectroscopy systems, and Creative Biostructure, a structural biology Contract Research Organization, today announced a strategic partnership to support broader adoption of EPR spectroscopy for studying protein dynamics in pharmaceutical and biotechnology research. EPR spectroscopy is increasingly relevant as drug discovery turns toward disordered, flexible, and disease‑relevant protein systems that cannot be fully understood through static structural methods alone. However, broad adoption of EPR has historically been limited by instrument and workflow complexity, and the need for dedicated technical expertise in experimental design and data interpretation. Leveraging quantum sensor technology, FATHOM® EPR has overcome these challenges. By providing unique measurements of long‑range distances, FATHOM® EPR enables researchers to probe conformational ensembles and molecular motion implicated in toda
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom